Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters

Circulation

Volumn 102, Issue 2, 2000, Pages 246-252

  Taniyama, Yoshiaki ^a   Morishita, Ryuichi ^a   Nakagami, Hironori ^a   Moriguchi, Atsushi ^a   Sakonjo, Hiroshi ^b   Shokei Kim, ^c   Matsumoto, Kunio ^c   Nakamura, Toshikazu ^c   Higaki, Jitsuo ^c   Ogihara, Toshio ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b Kankyo Bailis   (Japan)

^c NONE

Author keywords

Collagen; Extracellular matrix; Fibrosis; Metalloproteinases; Remodeling

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; OLMESARTAN; SCATTER FACTOR; TEMOCAPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBROGENESIS; HAMSTER; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034636783     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.2.246     Document Type: Article

References (46)

1. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the HGF/SF receptor family. Cell. 1994;77:261-271.
2. Rosen EM, Nigani SK, Goldberg ID. Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction. J Cell Biol. 1994;127:1783-1787.
3. Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) as tissue organizer for organogenesis and regeneration. Biochem Biophys Res Commun. 1997;239:639-644.
4. Matsuda Y, Matsumoto K, Ichida T, et al. Hepatocyte growth factor suppresses the onset of liver cirrhosis and abrogates lethal hepatic dysfunction in rats. J Biochem Tokyo. 1995;118:643-649.
5. Yaekashiwa M, Nakayama S, Ohnuma K, et al. Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin: a morphologic study. Am J Respir Crit Care Med. 1997;156:1937-1944.
6. Matsuda Y, Matsumoto K, Yamada A, et al. Preventive and therapeutic effects in rats of hepatocyte growth factor infusion on liver fibrosis/ cirrhosis. Hepatology. 1997;26:81-89.
7. Ueki T, Kaneda Y, Tsutsui H, et al. Curative gene therapy of liver cirrhosis by hepatocyte growth factor in rats. Nat Med. 1999;5:226-230.
8. Wunsch M, Sharma HS, Marken T, et al. In situ localization of transforming growth factor beta 1 in porcine heart: enhanced expression after chronic coronary artery constriction. J Mol Cell Cardiol. 1991;23:1051-1062.
9. Booz GW, Baker KM. Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res. 1995;30:537-543.
10. Li RK, Li G, Mickle DA, et al. Overexpression of transforming growth factor-β1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation. 1997;96:874-881.
11. Hanatani A, Yoshiyama M, Kim S, et al. Inhibition by angiotensin II type 1 receptor antagonist of cardiac phenotypic modulation after myocardial infarction. J Mol Cell Cardiol. 1995;27:1905-1914.
12. Shiota N, Fukamizu A, Takai S, et al. Activation of angiotensin II-forming chymase in the cardiomyopathic hamster heart. J Hypertens. 1997;15:431-440.
13. Danser AH, van-Kesteren CA, Bax WA, et al. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts: evidence for renin binding. Circulation. 1997;96:220-226.
14. Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest. 1993;91:1269-1281.
15. Ohkubo N, Matsubara H, Nozawa Y, et al. Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation. 1997;96:3954-3962.
16. Nakamura F, Nagano M, Kobayashi R, et al. Chronic administration of angiotensin II receptor antagonist, TCV-116, in cardiomyopathic hamsters. Am J Physiol. 1994;267:H2297-H2304.
17. Nakano N, Moriguchi A, Morishita R, et al. Role of angiotensin II in the regulation of a novel vascular modulator, hepatocyte growth factor, in experimental hypertensive rats. Hypertension. 1997;30:1448-1454.
18. Nakano N, Morishita R, Moriguchi A, et al. Negative regulation of local hepatocyte growth factor expression by angiotensin II and transforming growth factor-β in blood vessels: potential role of HGF in cardiovascular disease. Hypertension. 1998;32:444-451.
19. Tremble PM, Lane TF, Sage EH, et al. SPARC, a secreted protein associated with morphogenesis and tissue remodeling induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J Cell Biol. 1993;121:1433-1444.
20. Kunisada K, Tone E, Fujio Y, et al. Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation. 1998;98:346-352.
21. Libby P, O'Brien KV. Culture of quiescent arterial smooth muscle cells in a defined serum-free medium. J Cell Physiol. 1983;115:217-223.
22. Ishiyama M, Shiga M, Sasamoto K, et al. A new sulfonated tetrazolium salt that produces a highly water-soluble formazan dye. Chem Pharm Bull. 1993;41:1118-1122.
23. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor beta 1 expression determines growth response to angiotensin II. J Clin Invest. 1992;90:456-461.
24. Yamada A, Matsumoto K, Iwanari H, et al. Rapid and sensitive enzyme-linked immunosorbent assay for measurement of HGF in rat and human tissues. Biomed Res. 1995;16:105-114.
25. Nakamura Y, Morishita R, Higaki J, et al. Expression of local hepatocyte growth factor system in vascular tissues. Biochem Biophys Res Commun. 1995;215:483-488.
26. Yoshikane H, Honda M, Goto Y, et al. Collagen in dilated cardiomyopathy: scanning electron microscopic and immunohistochemical observations. Jpn Circ J. 1992;56:899-910.
27. Alpert NR, Mulieri LA, Hasenfuss G, et al. Myocyte reorganization in hypertrophied and failing hearts. Eur Heart J. 1995;16:C2-C7.
28. Oldfors A, Eriksson BO, Kyllerman M, et al. Dilated cardiomyopathy and the dystrophin gene: an illustrated review. Br Heart J. 1994;72:344-348.
29. Dixon IM, Ju H, Reid NL, et al. Cardiac collagen remodeling in the cardiomyopathic Syrian hamster and the effect of losartan. J Mol Cell Cardiol. 1997;29:1837-1850.
30. Nogami K, Kusachi S, Niiya K, et al. Changes in extracellular matrix components in cardiomyopathic Syrian hamster, BIO 14.6. Jpn Circ J. 1995;59:631-640.
31. Besser D, Bardelli A, Didichenko S, et al. Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2. Oncogene. 1997;14:705-711.
32. Jeffers M, Rong S. Vande-Woude GF. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol. 1996;16:1115-1125.
33. Naldini L, Vigna E, Bardelli A, et al. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem. 1995;270:603-611.
34. Lewin B. Oncogenic conversion by regulatory changes in transcription factors. Cell. 1991;64:303-312.
35. Iwasaka C, Tanaka K, Abe M, et al. Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J Cell Physiol. 1996;169:522-531.
36. Wasylyk B, Wasylyk C, Flores P, et al. The c-ets proto-oncogenes encode transcription factors that cooperate with c-Fos and c-Jun for transcriptional activation. Nature. 1990;346:191-193.
37. Wasylyk C, Kerckaert JP, Wasylyk B. A novel modulator domain of Ets transcription factors. Genes Dev. 1992;6:965-974.
38. Vandenbunder B, Wernert N, Queva C, et al. Does the transcription factor c-ets 1 take part in the regulation of angiogenesis and tumor invasion? Folia Biol Praha. 1994;40:301-313.
39. Nerlov C, Rorth P, Blasi F, et al. Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene. 1991;6:1583-1592.
40. Gum R, Lengyel E, Juarez J, et al. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem. 1996;271:10672-10680.
41. Vantrimpont P, Rouleau JL, Wun CC, et al, for the SAVE Investigators. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. J Am Coll Cardiol. 1997;29:229-236.
42. Jensen BV, Nielsen SL, Skovsgaard T. Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet. 1996;347:297-299.
43. Lewis AB, Chabot M. The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy. Pediatr Cardiol. 1993;14:9-12.
44. Riegger GA. Effects of quinapril on exercise tolerance in patients with mild to moderate heart failure. Eur Heart J. 1991;12:705-711.
45. Panizo A, Pardo J, Hernandez M, et al. Quinapril decreases myocardial accumulation of extracellular matrix components in spontaneously hypertensive rats. Am J Hypertens. 1995;8:815-822.
46. Tsutsumi Y, Matsubara H, Masaki H, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest. 1999;104:925-935.